Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Lam Research Corporation (LRCX) A Good Stock To Buy?

We at Insider Monkey have gone over 742 13F filings that hedge funds and prominent investors are required to file by the government. The 13F filings show the funds’ and investors’ portfolio positions as of September 30. In this article, we look at what those funds think of Lam Research Corporation (NASDAQ:LRCX) based on that data.

Hedge fund interest towards Lam Research Corporation (NASDAQ:LRCX) shares remained unchanged during the third quarter. This is usually a negative indicator. However, before jumping to any conclusions, at the end of this article we will also compare LRCX to other stocks including EQT Corporation (NYSE:EQT), Laboratory Corp. of America Holdings (NYSE:LH), and Markel Corporation (NYSE:MKL) to get a better sense of its popularity.

Follow Lam Research Corp (NASDAQ:LRCX)
Trade (NASDAQ:LRCX) Now!

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 18% gains over the past 12 months, more than doubling the 8% returns enjoyed by the S&P 500 ETFs.

engineering, semiconductor, network, flash, circuit, complexity, board, networking, integrated, community, hardware, future, laboratory, multimedia, internet, social,


Keeping this in mind, let’s review the key action surrounding Lam Research Corporation (NASDAQ:LRCX).

Hedge fund activity in Lam Research Corporation (NASDAQ:LRCX)

Overall, 47 funds tracked by Insider Monkey held long positions in Lam Research Corporation at the end of September, unchanged over the quarter. Interestingly, as you can see from the graph below, hedge fund interest in LRCX has been extremely stable over the last 5 quarters. With the smart money’s positions undergoing their usual ebb and flow, there exists a few key hedge fund managers who were boosting their stakes substantially (or already accumulated large positions).


When looking at the institutional investors followed by Insider Monkey, Lee Ainslie’s Maverick Capital has the biggest position in Lam Research Corporation (NASDAQ:LRCX), worth close to $430.5 million, comprising 5.1% of its total 13F portfolio. The second most bullish fund manager is Two Sigma Advisors, managed by John Overdeck and David Siegel, which holds a $188.9 million position. Remaining hedge funds and institutional investors that hold long positions contain Principal Global Investors’ Columbus Circle Investors, Cliff Asness’ AQR Capital Management, and Ken Griffin’s Citadel Investment Group.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.